Articles by The Wall Street Analyzer

About The Wall Street Analyzer
The Wall Street Analyzer's staff of writers, analysts, publishers, producers, market researchers, and PR professionals aim to provide investors with the tools they need to make informed decisions on buying stock. Our staff is a mix of financial professionals and media savvy individuals whose experiences bring the best talent from both ends of the spectrum.
News Feed

Canadian Gold Corp. Tartan South Zone Continues to Hit: 140m Vertical Expansion Intersects 9.4 gpt Gold/ 3.3m

May 13, 2025 The Wall Street Analyzer Comments Off on Canadian Gold Corp. Tartan South Zone Continues to Hit: 140m Vertical Expansion Intersects 9.4 gpt Gold/ 3.3m

South Zone Now 310m (120%) Below 2017 Resource Flin Flon, Manitoba–(Newsfile Corp. – May 12, 2025) – Canadian Gold Corp. (TSXV: CGC) (“Canadian Gold” or the “Company”) is pleased to announce ongoing drill results from […]

News Feed

Pasofino Gold Announces Non-Brokered Private Placement for Gross Proceeds of Approximately C$5.0 Million

April 30, 2025 The Wall Street Analyzer Comments Off on Pasofino Gold Announces Non-Brokered Private Placement for Gross Proceeds of Approximately C$5.0 Million

Toronto, Ontario–(Newsfile Corp. – April 30, 2025) – Pasofino Gold Limited (TSXV: VEIN) (FSE: N07A) (“Pasofino” or the “Company“) is pleased to announce a non-brokered private placement of units (each, a “Unit“) at C$0.50 (or […]

Market News

Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks

April 14, 2025 The Wall Street Analyzer Comments Off on Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks

Interim Results from FDA-Funded Study Reinforces HyBryte’s™ Rapid Response and Strong Safety Profile PRINCETON, N.J., April 14, 2025 /PRNewswire/ — Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat […]